Hepatocellular carcinoma (HCC) is a major cause of death in many countries, including South Korea. To provide useful and sensible advice for clinical management of patients with HCC, the Korean Liver Cancer Association and National Cancer Center Korea Practice Guideline Revision Committee have recently revised the practice guidelines for HCC management. However, there are some differences between practice guidelines and real-life clinical practice. In this review, we describe some key recommendations of the 2022 version of practice guidelines and the real-life clinical situation in South Korea, together with discussion about efforts needed to reduce the difference between guidelines and real-life clinical practice.
Citations
Citations to this article as recorded by
Neutrophil count predicts the complete response after transarterial chemoembolization related to favorable outcome in hepatocellular carcinoma Young Mi Hong European Journal of Gastroenterology & Hepatology.2025; 37(1): 94. CrossRef
Epidemiological characteristics and precise prophylaxis and control of HBV-associated primary liver cancer Yuqi Feng, Letian Fang, Guangwen Cao Hepatoma Research.2025;[Epub] CrossRef
A Prospective, Multicenter, Randomized, Noninferiority Trial of Stopad® Versus Tachosil® for Hemostasis After Liver Resection Seung Yeon Lim, Gi Hong Choi, Jin Hong Lim, Ho-Seong Han, Yoo-Seok Yoon, Hae Won Lee, Boram Lee, Yeshong Park, MeeYoung Kang, Jinju Kim, Hyelim Joo, Jai Young Cho Cancers.2025; 17(5): 757. CrossRef
Reply: Intrahepatic IgA complex induces polarization of cancer-associated fibroblasts to matrix phenotypes in the tumor microenvironment of hepatocellular carcinoma Deok Hwa Seo, Pil Soo Sung Hepatology.2025; 81(4): E123. CrossRef
The Association Between Hepatocellular Carcinoma and Gastrointestinal Adenocarcinoma: Is This a New Syndrome in Patients With Cirrhosis? A Case Series Fabrizio Bronte, Fabio D'Amato, Maria Rosa Barcellona, Giuseppe Bronte, Giuseppe Malizia, Salvatore Ialuna, Giorgio Fusco, Francesco Verderame, Enrico Bronte, Maria Grazia Bavetta Cancer Reports.2025;[Epub] CrossRef
Roadmap for HCC Surveillance and Management in the Asia Pacific Masatoshi Kudo, Bui Thi Oanh, Chien-Jen Chen, Do Thi Ngat, Jacob George, Do Young Kim, Luckxawan Pimsawadi, Pisit Tangkijvanich, Raoh-Fang Pwu, Rosmawati Mohamed, Sakarn Bunnag, Sheng-Nan Lu, Sirintip Kudtiyakarn, Tatsuya Kanto, Teerha Piratvisuth, Chao-C Cancers.2025; 17(12): 1928. CrossRef
TCR-based cellular immunotherapy for hepatocellular carcinoma: advances, challenges, and prospects Wanting Zeng, Wei Zhu, Guosheng Yuan, Jinzhang Chen, Zhanhui Wang, Jinlin Hou, De-Ke Jiang Cancer Immunology, Immunotherapy.2025;[Epub] CrossRef
Development and validation of a risk prediction model for patients with hepatocellular carcinoma receiving atezolizumab–bevacizumab Heechul Nam, Dong Yun Kim, Do Young Kim, Ji Hoon Kim, Chang Wook Kim, Jaejun Lee, Keungmo Yang, Ji Won Han, Pil Soo Sung, Seung Kew Yoon, Hee Sun Cho, Hyun Yang, Si Hyun Bae, Soon Kyu Lee, Jung Hyun Kwon, Soon Woo Nam, Ahlim Lee, Do Seon Song, U Im Chang, Hepatology.2025;[Epub] CrossRef
Subset of Child-Pugh Score 7 Shows Comparable Survival Outcomes to Child-Pugh Score 6 in Patients with Hepatocellular Carcinoma Treated with Atezolizumab and Bevacizumab Jaejun Lee, Keungmo Yang, Ji Won Han, Pil Soo Sung, Jeong Won Jang, Seung Kew Yoon, Hee Sun Cho, Hyun Yang, Si Hyun Bae, Ji Hoon Kim, Heechul Nam, Chang Wook Kim, Hae Lim Lee, Hee Yeon Kim, Sung Won Lee, Ahlim Lee, Do Seon Song, Myeong Jun Song, Soon Woo Clinical Cancer Research.2025; 31(20): 4323. CrossRef
Atezolizumab Plus Bevacizumab for Advanced Hepatocellular Carcinoma with Macroscopic Vascular Invasion: An Inverse Probability of Treatment Weighted Analysis Jihoon Kim, Jin-Hyoung Kim, Byung Soo Im, Gun Ha Kim, Hee Ho Chu, Dong Il Gwon, Ji Hoon Shin, Ju Hyun Shim, Sang Min Yoon, Sehee Kim Cancers.2025; 18(1): 33. CrossRef
The Position of Multikinase Inhibitors in the Era of Immune-Checkpoint Inhibitors for Hepatocellular Carcinoma Beom Kyung Kim Gut and Liver.2024; 18(1): 3. CrossRef
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma Josep M. Llovet, Roser Pinyol, Mark Yarchoan, Amit G. Singal, Thomas U. Marron, Myron Schwartz, Eli Pikarsky, Masatoshi Kudo, Richard S. Finn Nature Reviews Clinical Oncology.2024; 21(4): 294. CrossRef
High‐dose proton pump inhibitor treatment is associated with a higher mortality in cirrhotic patients: A multicentre study Jun Sik Yoon, Ji Hoon Hong, Soo Young Park, Seung Up Kim, Hwi Young Kim, Ju Yeon Kim, Moon Haeng Hur, Min Kyung Park, Yun Bin Lee, Han Ah Lee, Gi‐Ae Kim, Dong Hyun Sinn, Sung Jae Park, Youn Jae Lee, Yoon Jun Kim, Jung‐Hwan Yoon, Jeong‐Hoon Lee Alimentary Pharmacology & Therapeutics.2024; 59(8): 973. CrossRef
Role of reimbursement and Physicians' awareness in the survival of sorafenib‐eligible advanced hepatocellular carcinoma patients Hui‐Ling Huang, Te‐Sheng Chang, Lariza Marie Canseco, Fan Wu, Sheng‐Nan Lu The Kaohsiung Journal of Medical Sciences.2024; 40(6): 589. CrossRef
Limited Generalizability of Retrospective Single-Center Cohort Study in Comparison to Multicenter Cohort Study on Prognosis of Hepatocellular Carcinoma Ye Rim Kim, Sung Won Chung, Min-Ju Kim, Won-Mook Choi, Jonggi Choi, Danbi Lee, Han Chu Lee, Ju Hyun Shim Journal of Hepatocellular Carcinoma.2024; Volume 11: 1235. CrossRef
Similar recurrence after curative treatment of HBV-related HCC, regardless of HBV replication activity Mi Na Kim, Beom Kyung Kim, Heejin Cho, Myung Ji Goh, Yun Ho Roh, Su Jong Yu, Dong Hyun Sinn, Soo Young Park, Seung Up Kim, Tyng-Yuan Jang PLOS ONE.2024; 19(8): e0307712. CrossRef
The position of loco-regional therapy in the management of hepatocellular carcinoma with extrahepatic metastases Beom Kyung Kim Journal of Liver Cancer.2024; 24(2): 129. CrossRef
Role of transarterial chemoembolization for hepatocellular carcinoma with extrahepatic metastases in the era of advancing systemic therapy Byeong Geun Song, Myung Ji Goh, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Joon Hyeok Lee, Moon Seok Choi Journal of Liver Cancer.2024; 24(2): 243. CrossRef
Primary treatments for solitary hepatocellular carcinoma ≤ 3 cm: A systematic review and network meta-analysis Sang-Hoon Kim, Ki-Hun Kim, Byeong-Gon Na, Sung Min Kim, Rak-Kyun Oh Annals of Hepato-Biliary-Pancreatic Surgery.2024; 28(4): 397. CrossRef
Evolution of Liver Resection for Hepatocellular Carcinoma: Change Point Analysis of Textbook Outcome over Twenty Years Yeshong Park, Ho-Seong Han, Seung Yeon Lim, Hyelim Joo, Jinju Kim, MeeYoung Kang, Boram Lee, Hae Won Lee, Yoo-Seok Yoon, Jai Young Cho Medicina.2024; 61(1): 12. CrossRef
A Real-World Comparative Analysis of Atezolizumab Plus Bevacizumab and Transarterial Chemoembolization Plus Radiotherapy in Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombosis Soon Kyu Lee, Jung Hyun Kwon, Sung Won Lee, Hae Lim Lee, Hee Yeon Kim, Chang Wook Kim, Do Seon Song, U Im Chang, Jin Mo Yang, Soon Woo Nam, Seok-Hwan Kim, Myeong Jun Song, Ji Hoon Kim, Ahlim Lee, Hyun Yang, Si Hyun Bae, Ji Won Han, Heechul Nam, Pil Soo Su Cancers.2023; 15(17): 4423. CrossRef
What should be done to reduce the discrepancy between guidelines and real-life practice for hepatocellular carcinoma in Korea? Min Kyung Park, Yoon Jun Kim Clinical and Molecular Hepatology.2023; 29(2): 332. CrossRef
The current trends in the health burden of primary liver cancer across the globe Peter Konyn, Aijaz Ahmed, Donghee Kim Clinical and Molecular Hepatology.2023; 29(2): 358. CrossRef
Toward user-friendly and evidence-based practice guidelines for hepatocellular carcinoma Do Young Kim Clinical and Molecular Hepatology.2023; 29(2): 335. CrossRef
A Phase I/IIa Trial of Yttrium-90 Radioembolization in Combination with Durvalumab for Locally Advanced Unresectable Hepatocellular Carcinoma Yun Bin Lee, Joon Yeul Nam, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Hyo-Cheol Kim, Jin Chul Paeng, Jung-Hwan Yoon, Yoon Jun Kim Clinical Cancer Research.2023; 29(18): 3650. CrossRef
Tips for Preparing and Practicing Thermal Ablation Therapy of Hepatocellular Carcinoma Yasunori Minami, Tomoko Aoki, Satoru Hagiwara, Masatoshi Kudo Cancers.2023; 15(19): 4763. CrossRef
First
Prev
